丙型肝炎病毒总核心抗原测定方法及临床应用

目的建立丙型肝炎病毒总核心抗原（总HCV-cAg）酶联免疫测定方法，并对相关的临床样品进行测定。方法通过对样品进行裂解处理，采用酶联免疫试剂盒（ELISA）检测总HCV-cAg，对201名抗-HCV阳性者血清进行总HCV—cAg检测，同时进一步作HCV-RNA检测，其中176例采用荧光定量PCR（FQ—PCR），25例采用逆转录PCR（RT—PCR）检测HCV．RNA。结果共检测201份血清标本，其中经PCR测定HCVRNA阳性88人份，阳性率43．8％；总HCV—cAg阳性71份，阳性率35．3％。经统计学分析，总HCV—cAg检测和HCVRNA检测的阳性率的差异无统计学意义。结论建立的总HCV—cAg酶联免疫测定方法适合临床应用，尤其适合在缺少RT-PCR或荧光定量PCR的中小医院使用。

Clinical application of detection for total core antigen of hepatitis C virus

Objective To develop the technique to detect total core antigen of HCV(Total HCV-cAg) by Enzyme-Linked Immu-nosorbent Assay (ELISA) and apply it for clinical diagnosis. Methods 201 serum samples with anti-HCV antibody were detected total HCV-cAg after pre - treating the samples, then the sensitivity of results were compared with HCV RNA tests. Among them, 176 cases was determined by FQ-PCR, and 25 cases by RT-PCR for HCV-RNA. Results HCV RNA was found in sera from 88 of 201 samples (43.8%). Total HCV-cAg was positive in 71 (35.3%) of 201 samples . There was no significant difference between the detection rate of HCV RNA by PCR and total HCV-cAg by ELISA. Conclusion Detection of total core antigen of HCV is suitable to be used as to diagnose HCV in clinic.